SCHEMBL4673713

SCHEMBL4673713

Oc1ccc(-c2ccc(Sc3ccc(-c4cccc(O)c4)cc3)cc2)cc1

nearest known ligand 0.76

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 12/20 0.76
HSD17B2 P37059 11/20 0.76
CYP3A4 P08684 3/20 0.68
CYP2C9 P11712 3/20 0.68
ESR1 P03372 3/20 0.61
MEN1 O00255 1/20 0.61
KMT2A Q03164 1/20 0.61
ABL1 P00519 1/20 0.59
ABCB1 P08183 1/20 0.59
BCR P11274 1/20 0.59
ESR2 Q92731 3/20 0.57
CYP1A2 P05177 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2B6 P20813 1/20 0.57
CYP2C19 P33261 1/20 0.57
NR1H2 P55055 1/20 0.56
MMP3 P08254 1/20 0.48
BCL2L1 Q07817 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671659 0.96 HSD17B1 (0.74) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL21312574 0.90 HSD17B1 (0.61) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL4431853 0.89 ESR1 (0.70) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL21312571 0.88 ESR1 (0.61) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL70625 0.87 HSD17B1 (1.00) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL29404406 0.87 HSD17B1 (1.00) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL7129229 0.87 HSD17B1 (1.00) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL1180998 0.87 HSD17B1 (1.00) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL21312573 0.86 HSD17B1 (0.67) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
Hydrogen Sulfide SCHEMBL23879303 0.85 HSD17B1 (0.95) HSD17B1HSD17B2CYP3A4CYP2C9ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6881815-B2 Method for the preparation poly(etherimide)s GENERAL ELECTRIC COMPANY (US) 2005-04-19 US claimed
EP-1458791-A1 METHODS FOR THE PREPARATION OF POLY(ETHERIMIDES)S GENERAL ELECTRIC COMPANY (US) 2004-09-22 EP claimed
US-20040063897-A1 Method for the preparation poly(etherimide)s SHPP GLOBAL TECHNOLOGIES B.V. (NL) 2004-04-01 US claimed
US-6590108-B1 Transimidation of bis(imide) in presence of phthalic anhydride having substituent selected from group consisting of nitro, bromo, fluoro and chloro, to yield dianhydride GENERAL ELECTRIC COMPANY 2003-07-08 US claimed
WO-2003050165-A1 METHODS FOR THE PREPARATION OF POLY(ETHERIMIDES)S GENERAL ELECTRIC COMPANY (US) 2003-06-19 WO claimed
US-6498224-B1 SOLUTION POLYMERIZATION OF A DIANHYDRIDE AND A DIAMINE WHICH ELIMINATES THE NITRATION STEP; HIGH HEAT ENGINEERING PLASTICS GENERAL ELECTRIC COMPANY 2002-12-24 US claimed
EP-1403303-B1 Methods for the preparation of poly(etherimide)s GEN ELECTRIC (US) 2008-08-20 EP disclosed
EP-1458791-B1 METHODS FOR THE PREPARATION OF POLY(ETHERIMIDES)S GEN ELECTRIC (US) 2006-11-29 EP disclosed
US-6881815-B2 Method for the preparation poly(etherimide)s GENERAL ELECTRIC COMPANY (US) 2005-04-19 US disclosed
EP-1458791-A1 METHODS FOR THE PREPARATION OF POLY(ETHERIMIDES)S GENERAL ELECTRIC COMPANY (US) 2004-09-22 EP disclosed
US-20040063897-A1 Method for the preparation poly(etherimide)s SHPP GLOBAL TECHNOLOGIES B.V. (NL) 2004-04-01 US disclosed
EP-1403303-A1 Methods for the preparation of poly(etherimide)s General Electric Company (US) 2004-03-31 EP disclosed
US-6590108-B1 Transimidation of bis(imide) in presence of phthalic anhydride having substituent selected from group consisting of nitro, bromo, fluoro and chloro, to yield dianhydride GENERAL ELECTRIC COMPANY 2003-07-08 US disclosed
WO-2003050165-A1 METHODS FOR THE PREPARATION OF POLY(ETHERIMIDES)S GENERAL ELECTRIC COMPANY (US) 2003-06-19 WO disclosed
US-6498224-B1 SOLUTION POLYMERIZATION OF A DIANHYDRIDE AND A DIAMINE WHICH ELIMINATES THE NITRATION STEP; HIGH HEAT ENGINEERING PLASTICS GENERAL ELECTRIC COMPANY 2002-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063897-A1 Method for the preparation poly(etherimide)s FHIT, PBRM1, PMAIP1 HSD17B1 2281/4885HSD17B2 2364/4885CYP3A4 1074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.